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Introduction: Various reduced-intensity conditioning regimens
using umbilical cord blood include total body irradiation. How-
ever, the necessary of that remains to be deﬁned for engraftment
and achievement of complete donor chimerism. Patients and
Methods: In a phase I study to evaluate the feasibility and safety of
non-TBI-RICBT in patients with advanced hematological malig-
nancies, who were ineligible for conventional allogeneic hemato-
poietic stem cell transplantation, we treated a total of 8 patients (3
FL, 1 PTCL, 2 MDS, 1 CML, 1 multiple myeloma). Patients
received non-TBI-RICBT from April 2004 to January 2005 in St.
Marianna University Yokohama City Seibu Hospital. There were
4 females and 4 males, with a median age of 58 (46-62) years old.
At the transplantation, all patients were in high-risk. Backbone
agent in the conditioning regimen was ﬂudarabine, in combination
with melphalan (n 1), or melphalan and thiotepa (n 7). GVHD
prophylaxis incorporated cyclosporine alone (n  1), or FK506
alone (n  7). After serological typing for class I antigens, the
degree of HLA match between patients and cord blood units was
4/6 in 7 cases and 5/6 in a case. The median numbers of infused
total nucleated cell dose and CD34 cell dose before freezing were
2.96  107/kg and 0.72  105/kg, respectively. Results: All of the
patients achieved primary neutrophil engraftment. The median
time to reach 0.5  109/L neutrophils was 26 days. Platelet counts
above 20  109/L were achieved by 5 patients on median time of
44 days. The median time to complete donor chimerism was 29
(22-33) days. Acute GVHD occurred in 2 of the 8 patients (grade
I/II in 2). Chronic GVHD developed in 2 of the evaluable patients.
Three patients died from transplantation related causes (1 invasive
aspergillus infection, 1 thrombotic microangiopathy, 1 acute heart
failure), and the other 3 patients died due to disease progression. At
a median follow-up of 129 days (29-224), one of the 8 patients is
currently alive in CR. Conclusions: Although this study is pre-
liminary with a small number of patients and short follow-up, our
ﬁndings demonstrated the successful engraftment of non-TBI-
RICBT for adult patients with advanced hematological malignan-
cies. Prospective study to further evaluate the efﬁcacy of non-TBI-
RICBT for hematological malignancies is warranted.
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IRON OVERLOAD MANIFESTING AS LIVER GRAFT VERSUS HOST DIS-
EASE EXACERBATION: RESPONSE TO ERYTHROPOIETIN ASSISTED
PHLEBOTOMY
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Eight patients with clinically signiﬁcant iron overload (IOL)
presenting as exacerbation of liver graft versus host disease
(GVHD) are described. IOL resulting from median of 20 units
lifetime packed red cell (PRBCs) transfusion manifested 14.5
months following allogeneic hematopoietic transplantation
(AHT). IOL (median serum ferritin 6702 g/dL, median trans-
ferrin saturation 89%) manifested clinically with worsening of
liver functions (n  8), bronze skin (n  8), glucose intolerance
(n 5), hepatocellular failure with ascites and encephalopathy (n
2) and impotence (n  2). Liver biopsy performed in 5 patients
revealed severe IOL and hepatic GVHD. Hemochromatosis gene
analysis for C282Y and H63D performed on pre-transplant stored
DNA (n 5) and buccal mucosa (n 3) was negative for homozy-
gous state in all 8 patients. All but 1 patient had chronic GVHD
(limited  6, extensive  1). Erythropoietin assisted phlebotomy
was well tolerated and resulted in normalization of liver functions
at median of 7 months and serum ferritin at median of 11 months.
Immunosuppressive therapy was successfully tapered in all 5 pa-
tients completing phlebotomy program. At median follow-up of 48
months (range17-77 months) from the transplant and 27 months
(range 3-34 months) after successful ferritin normalization, all 5
patients are requiring maintenance phlebotomy every 3-6 months.
In absence of dyserythropoiesis the reason for iron reaccumulation
is unclear. We hypothesize increased gastrointestinal iron absorp-
tion and or abnormality involving hepcidin in patients with
GVHD. Screening for IOL following AHT is recommended.
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The aim of this study was to evaluate the predictive value of a
sensitive chimerism method for relapse in 48 patients with AML
after allogeneic stem cell transplantation (SCT). The method,
based on real-time PCR using single nucleotide polymorphic
(SNP) markers, has previously been shown to be more than one log
more sensitive than most commonly used methods. Peripheral
blood (PB) and bone marrow (BM) samples were analysed in 49
patients of whom 31 relapsed post-SCT. In PB, mixed chimerism
(MC) was detected in 95% and in BM 100% of the patients who
relapsed. Interestingly, a high degree of MC was found in patients
without relapse (68% in PB and 82% in BM). In some patients still
in remission, MC was found 4-5 years after SCT. In paired BM-PB
samples, the level of recipient cells was a median of 5 (range
0.1-234) times higher in BM as compared to PB. Chimerism
results after three months post-SCT has previously been shown to
be associated with relapse in ALL. In ALL threshold levels asso-
ciated with relapse have been identiﬁed (0.1% in PB and 1% in
BM). However, we could not ﬁnd this association in AML patients.
A comparison between the SNP method and the more commonly
used methods showed that patient cells were much more frequently
detected with the SNP method. 414 samples were analysed with
both methods. In 130 samples, MC was only detected with the
SNP method. In conclusion, a high incidence of MC was found
post-SCT with the SNP method. Unfortunately, we could not see
a clear association between MC results and relapse.
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OUTCOMES OF UMBILICAL-CORD BLOOD TRANSPLANTATION IN
ADULT PATIENTS WITH HEMATOLOGICAL MALIGNANCIES; A SINGLE
CENTER EXPERIENCE
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Osaka Medical Center for Cancer & CVD, Osaka, Japan.
Objectives: Promising results of transplants from umbilical-cord
blood (UCBT) have been reported in adults. This paper reports
the outcomes in our center. Methods: A total of 12 patients with
hematological malignancies, treated with myeloablation and trans-
plantation with unrelated HLA partially matched UCB during
2000-2005, were evaluated for hematological reconstitution, graft-
versus-host disease, life-threatening infections, transplant-related
mortality (TRM), and event-free survival (EFS). The outcomes
were also compared with that of 42 patients who received a my-
eloablative BMT form an HLA-matched unrelated donor
(UBMT) during the same period. Results: Eight patients received
UCBT at an early disease stage (the ﬁrst or second complete
remission, or chronic phase). Two of them received two units of
UCB simultaneously. One patient died of cerebral bleeding during
the conditioning. The remaining three patients received UCBT at
a late stage. Engraftment was achieved by day 100 in 10 of 11 UCB
recipients, compared with 40 of 42 UBM recipients. The median of
neutropenia 500/mm3 was 30 days after UCBT and 17 days after
UBMT. The longer neutropenia was associated with a longer
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